Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + doxorubicin + vincristine + prednisone + cyclophosphamide + lamivudine + zidovudine + interferon alfa-2a
- Development stage
- Unknown
- Lead developer
- AIDS Malignancy Consortium
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This combination treatment regimen was developed by the AIDS Malignancy Consortium (AMC) for the treatment of adult T-cell leukemia/lymphoma (ATLL) associated with Human T-cell leukemia virus type 1 (HTLV-1) infection. The protocol involves an induction phase using the EPOCH chemotherapy regimen (etoposide, doxorubicin, vincristine, prednisone, and cyclophosphamide) to achieve maximal clinical response, followed by a maintenance phase consisting of the antiviral drugs lamivudine and zidovudine (often administered as the combination product Combivir) along with interferon alfa-2a. Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that target the HTLV-1 reverse transcriptase, while interferon alfa-2a provides immunomodulatory and antiproliferative effects. The regimen aims to control both the malignant T-cell clone and the underlying viral replication, addressing the unique pathophysiology of HTLV-1-driven malignancy.
- Brand names
- CombivirRoferon-A
- Other names
- AMC-034 regimenAMC034 regimenAMC 034 regimenEPOCH plus maintenance lamivudine, zidovudine, and interferon alfa-2aEPOCH-Combivir-IFN regimen
02
Targets
TOP2A (DNA topoisomerase II)Human immunodeficiency virus type 1 reverse transcriptaseGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))TOP2B (DNA topoisomerase II beta)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on etoposide + doxorubicin + vincristine + prednisone + cyclophosphamide + lamivudine + zidovudine + interferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + doxorubicin + vincristine + prednisone + cyclophosphamide + lamivudine + zidovudine + interferon alfa-2a.